AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03664531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocebo
Description: 1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
Study NCT02439697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Conversion from Aranesp® to NESP®
Study NCT00520949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin (Amoxicillin-clavulanic)
Description: Amoxicillin-clavulanic acid 1 gram b.i.d
Study NCT00520949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furoxone (furazolidone)
Description: furazolidone 200 mg b.i.d
Study NCT00520949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebes (colloidal bismuth subcitrate)
Description: colloidal bismuth subcitrate 240 mg b.i.d
Study NCT00520949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esso (esomeprazole)
Description: esomeprazole 40 mg b.i.d for 14 days
Study NCT00202280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
Study NCT00202280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
Study NCT01870349 — intervention group
Intervention type: PROCEDURE
Intervention: Gingival Crevicular Fluid Sampling
Description: Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
Study NCT02979977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
Study NCT02979977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
Study NCT04434482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(senaparib)
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study NCT02152891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAP-EMS/CP@clinic
Description: Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
Study NCT03246971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 50 mg
Description: Administered as needed for 12 hours
Study NCT03246971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 75 mg
Description: Administered as needed for 12 hours
Study NCT03246971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered as needed for 12 hours
Study NCT03246971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 25 mg
Description: Administered as needed for 12 hours
Study NCT02226393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
Study NCT02226393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-parent Play Therapy
Description: Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
Study NCT03630289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Description: Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Study NCT01870206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent OPV Birmex
Description: Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
Study NCT01870206 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent OPV Sanofi Pasteur
Description: Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
Study NCT00976183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
Study NCT00976183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
Study NCT04340895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal Calprotectin Home Test
Description: A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator.
Study NCT04340895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-2 Scoring
Description: Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
Study NCT04340895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRO-2 Scoring
Description: Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin was administered intravenously over 30 (± 5) minutes.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxacillin
Description: Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: Cefadroxil was administered orally every 12 hours.
Study NCT02814916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin was administered orally every 8 hours.
Study NCT03058029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Subject would take Gelesis200 capsules 2 times per day.
Study NCT03058029 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject would take placebo capsules 2 times per day.
Study NCT03583099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD plus CAPTURE education and patient-level information
Description: Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
Study NCT03583099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD Education Only
Description: Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
Study NCT04587518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Cognitive Behavioral Therapy
Description: The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
Study NCT04776083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: first line systemic therapy
Description: first line systemic therapy according to the genetic mutation 0f the patient
Study NCT04776083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first line systemic therapy
Description: first line systemic therapy according to the genetic mutation 0f the patient
Study NCT04776083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D radiotherapy or IMRT
Description: Hypo-fractionated radiotherapy to the primary lesion
Study NCT04019379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Phosphorus Diet
Description: Controlled research diet of high phosphorus (with low calcium)
Study NCT04019379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Phosphorus Diet
Description: Controlled research diet of low phosphorus (with low calcium)
Study NCT04750824 — intervention group
Intervention type: DRUG
Intervention: Afatinib
Description: Afatinib
Study NCT04750824 — intervention group
Intervention type: DRUG
Intervention: other systemic therapy
Description: other systemic therapy
Study NCT04557410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyMVA
Description: One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin.
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day for 7 days prior to transplantation
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day after transplant
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day after transplant
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
Study NCT01149993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
Study NCT04935034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
Study NCT04935034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
Study NCT04055220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment by Regorafenib
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Study NCT04055220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment by Placebo
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Study NCT04087018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zimberelimab
Description: zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
Study NCT02753283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Study NCT02753283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semi-annual saline injection
Study NCT02753283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Study NCT02753283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Study NCT04144569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Combined With Pyrotinib
Description: PD-1 Combined With Pyrotinib
Study NCT04533919 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of dorsal root ganglia
Study NCT04090203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boiled Peanut Powder
Description: Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
Study NCT03299556 — intervention group
Intervention type: OTHER
Intervention: WHT
Description: Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
Study NCT01508689 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receive Kellogg's Nutri-Grain® cereal bars first
Description: First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
Study NCT01508689 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receive Kellogg's Nutri-Grain® cereal bars second
Description: First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
Study NCT03466658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JumpStart Antimicrobial Wound Dressing
Description: A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
Study NCT00837434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg dose of etanercept by subcutaneous injection
Study NCT00837434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg dose of adalimumab by subcutaneous injection
Study NCT02595125 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IUD
Description: copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
Study NCT02595125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
Study NCT06256185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: Resection of esophageal tumor and lymph node dissection
Study NCT03181022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
Study NCT01779830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsules
Description: Administered orally as capsules.
Study NCT01779830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem - Tablets
Description: Administered orally as tablets.
Study NCT01779830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsules
Description: Administered orally as capsules.
Study NCT01779830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Tablets
Description: Administered orally as tablets.
Study NCT04277975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal post-discharge opioid prescribing
Description: Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
Study NCT04277975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted post-discharge opioid prescribing
Description: Opioid only if needed after discharge
Study NCT01082861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Cervarix, HPV vaccin
Study NCT01082861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B, HBV vaccin